GRAPHCMS
24.11.2021 18:02:09 CET | Business Wire | Press release
GraphCMS — the Berlin-based company behind the headless GraphQL content federation platform that helps leading companies unify the content layer by federating business-critical APIs — announced today that they have joined the MACH alliance , an independent group of tech companies advocating for an open and best-of-breed enterprise technology ecosystem. As part of the MACH alliance, GraphCMS will work closely with the other members to guide companies on how they can benefit from a lean and modular approach to enterprise technologies, by adopting MACH (microservices, API-first, Cloud-native SaaS, and Headless) architectures.
Liberating data effectively from legacy and third-party systems is a key challenge for digitally-driven enterprises as they strive towards creating immersive, high-performance digital experiences. GraphCMS’s leading content management capabilities and novel approach to remote data fetching from external systems such as other MACH vendors — dubbed “Content Federation ” — enables microservices to talk to each other, helping organizations deliver cutting-edge digital experiences across platforms, from streaming services to innovative new eCommerce platforms in a fraction of the time. Companies can build complex applications while aggregating their data from multiple sources into a single API, effectively eliminating content silos and “API Sprawl”.
“The MACH alliance’s ethos of encouraging companies in adopting modern, composable microservices rather than monolithic suites is extremely aligned with our own vision at GraphCMS, as we work with our customers in modernizing their stacks using best-of-breed solutions ”, explains Christopher Kühn , CCO at GraphCMS.
Already supporting companies like Telenor , Burrow , 2U Inc. , and Prym in their ambitious initiatives to deliver better digital experiences to millions of consumers via Content Federation, GraphCMS aims to accelerate the enterprise adoption of MACH compliant software architectures as the “glue” that federates them together into a single GraphQL API.
“We’re thrilled to be joining the MACH Alliance. Their approach represents the future of software, where companies are in charge of defining composable tech stacks that are perfectly aligned with scaling their business model, rather than adapting to inflexible monolithic suites ”, adds Ronak Ganatra, VP of Marketing at GraphCMS.
About GraphCMS
GraphCMS is the first enterprise-class headless content management and federation platform that enables data unification from multiple APIs. With the industry's most versatile GraphQL content APIs and a novel approach in external data sourcing via API extensions, the content platform enables use cases beyond simple headless CMS' capabilities. Enterprise customers see GraphCMS as a database highly optimized for structured content while giving content creators the tools to build their ultimate content pipeline. GraphCMS is developed by GraphCMS GmbH, headquartered in Berlin, Germany, and is currently enabling over 50,000 teams across the world to rapidly build and deliver tomorrow’s omnichannel digital experiences at scale.
About the MACH Alliance
The MACH Alliance is a [501(c)(6)] non-profit organization, governed by an independent board and does not endorse specific vendors, members, or otherwise. The Alliance was formed in June 2020 to help enterprise organizations navigate the complex modern technology landscape. It aims to guide and show the business advantage of open tech ecosystems that are Microservices based, API-first, Cloud-native, and Headless. All MACH Alliance members meet certification principles that are published on the website.
Founding members include Amplience, commercetools, Contentstack, EPAM Systems, and Valtech. The MACH Alliance welcomes technology companies and individual industry experts who share the same vision for the future. Learn more at machalliance.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211124005030/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom